| 1 |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| 2 |
喻星豪，黄娜，刘罡. 肺癌的靶向与免疫联合治疗的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(2): 330-333.
|
| 3 |
Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier[J]. Nat Cancer, 2022, 3(8): 911-926.
|
| 4 |
Xie N, Shen G, Gao W, et al. Neoantigens: promising targets for cancer therapy[J]. Signal Transduct Target Ther, 2023, 8(1): 1-38.
|
| 5 |
Saxena M, van der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378.
|
| 6 |
Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(6): 822-835.
|
| 7 |
Pujol JL, De Pas T, Rittmeyer A, et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: A phase I dose escalation study[J]. J Thorac Oncol, 2016, 11(12): 2208-2217.
|
| 8 |
Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage Ⅲnon-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(1): 59-68.
|
| 9 |
Thomas A, Giaccone G. Why has active immunotherapy not worked in lung cancer？[J]. Ann Oncol, 2015, 26(11): 2213-2220.
|
| 10 |
Finn OJ. Human tumor antigens yesterday, today, and tomorrow[J]. Cancer Immunol Res, 2017, 5(5): 347-354.
|
| 11 |
虞淦军，吴艳峰，曹雪涛. 个性化新抗原肿瘤疫苗：道阻且长，未来可期 [J]. 中国肿瘤生物治疗杂志，2022, 29(1): 1-10.
|
| 12 |
Liu WS, Tang HC, Li LF, et al. Peptide-based therapeutic cancer vaccine: Current trends in clinical application[J]. Cell Prolif, 2021, 54(5): e13025.
|
| 13 |
Gu WY, Xu YJ, Chen XH, et al. Characteristics of clinical trials for non-small cell lung cancer therapeutic vaccines registered on ClinicalTrials.gov[J]. Front Immunol, 2022, 13: 936667.
|
| 14 |
Brunsvig PF, Guren TK, Nyakas M, et al. Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer[J]. Front Immunol, 2020, 11：572172.
|
| 15 |
Gary ERJJP, Michael JB. IMPRINTER: An open label multicenter dose escalation/expansion phaseI study of IMU 201(PD1-Vaxx)aB cell[M]. Meeting Abstract: 2022 ASCO Annual Meeting, 2022, 40(16 Supplement): e21134.
|
| 16 |
Besse B, Felip E, Garcia Campelo R, et al. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1[J]. Ann Oncol, 2023, 34(10): 920-933.
|
| 17 |
Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer[J]. Cell, 2020, 183(2): 347-362 e324.
|
| 18 |
Awad MM, Govindan R, Balogh KN, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer[J]. Cancer Cell, 2022, 40(9): 1010-1026 e1011.
|
| 19 |
刘书鹏，余孟洋，吴晓霏，等. 肿瘤治疗性疫苗临床试验现状分析[J]. 协和医学杂志，2024, 15(6): 1356-1363.
|
| 20 |
Rodriguez PC, Popa X, Martinez O, et al. A phase Ⅲ clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients[J]. Clin Cancer Res, 2016, 22(15): 3782-3790.
|
| 21 |
Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity[J]. Semin Immunol, 2021, 52: 101481.
|
| 22 |
Philip WK, Celestia SH, Neal DS, et al. IMPACT study investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422.
|
| 23 |
Abascal J, Oh MS, Liclican EL, et al. Dendritic cell vaccination in non-small cell lung cancer: Remodeling the tumor immune microenvironment[J]. Cells, 2023, 12(19): 2404.
|
| 24 |
Zemanova M, Cernovska M, Havel L, et al. Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase Ⅰ/Ⅱ trial[J]. Cancer Treat Res Commun, 2021, 28: 100427.
|
| 25 |
Zhong R, Ling X, Cao S, et al. Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers[J]. ESMO Open, 2022, 7(1): 100334.
|
| 26 |
Ding ZY, Li Q, Zhang R, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer[J]. Signal Transduct Target Ther, 2021, 6(1): 26.
|
| 27 |
Ali OA, Lewin SA, Dranoff G, et al. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication[J]. Cancer Immunol Res, 2016, 4(2): 95-100.
|
| 28 |
Beck JD, Reidenbach D, Salomon N, et al. mRNA therapeutics in cancer immunotherapy[J]. Mol Cancer, 2021, 20(1): 69.
|
| 29 |
曹惠琳，吴艳峰. 肿瘤治疗性mRNA疫苗的研究进展[J]. 中国肿瘤生物治疗杂志，2023, 30(9): 810-816.
|
| 30 |
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine[J]. N Engl J Med, 2020, 383(27): 2603-2615.
|
| 31 |
Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study[J]. Lancet, 2024, 403(10427): 632-644.
|
| 32 |
Gainor JFPM, Weber JS. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study[J]. Cancer Discov, 2024, 14(11): 2209-2223.
|
| 33 |
Deme D, Öven B, Göker E, et al. Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer[Z]. Regular and Young Investigator Award Abstracts. 2023: A679-A679. 10.1136/jitc-2023-SITC2023.0597
|
| 34 |
Sebastian M, Schroder A, Scheel B, et al. A phase Ⅰ/Ⅱa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage ⅢB/Ⅳ non-small cell lung cancer[J]. Cancer Immunol Immunother, 2019, 68(5): 799-812.
|
| 35 |
Papachristofilou A, Hipp MM, Klinkhardt U, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage Ⅳ non-small cell lung cancer[J]. J Immunother Cancer, 2019, 7(1): 38.
|
| 36 |
Lopez J, Powles T, Braiteh F, et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial[J]. Nat Med, 2025, 31(1): 152-164.
|
| 37 |
Lorentzen CL, Haanen JB, Met O, et al. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment[J]. Lancet Oncol, 2022, 23(10): e450-e458.
|
| 38 |
Tran TAT, Kim YH, Kim GE, et al. The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model[J]. Front Immunol, 2022, 13: 1007285.
|
| 39 |
Aali F, Doosti A, Shakhsi-Niaei M. Bioinformatics analysis of innovative multi-epitope vaccine utilizing MAGE-A, MAM-A, and Gal-3 for breast cancer management[J]. Sci Rep, 2025, 15(1): 19774.
|
| 40 |
Wang X, Huang Z, Xing L, et al. STING agonist-based ER-targeting molecules boost antigen cross-presentation[J]. Nature, 2025, 641(8061): 202-210.
|
| 41 |
肖毅，吴名，姚刚. 肿瘤类器官研究现状与展望[J]. 中国癌症杂志，2024, 34(8): 763-776.
|
| 42 |
Fan T, Zhang M, Yang J, et al. Therapeutic cancer vaccines: advancements, challenges, and prospects[J]. Signal Transduct Target Ther, 2023, 8(1): 450.
|
| 43 |
Evans R, Lee K, Wallace PK, et al. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC[J]. Front Oncol, 2022, 12: 958043.
|
| 44 |
Guo S, Chen X, Guo C, et al. Tumour-associated macrophages heterogeneity drives resistance to clinical therapy[J]. Expert Rev Mol Med, 2022, 24: e17.
|
| 45 |
Zhang H, Zhang L, Lin A, et al. Algorithm for optimized mRNA design improves stability and immunogenicity[J]. Nature, 2023, 621(7978): 396-403.
|